In this feature, “Fast Money” uncovers some of The Street's most loved stocks. Although the analysts are smitten, you may never have heard of these titillating tickers. Following is Wall Street’s latest object of desire
Wednesday’s Streetheart is biotech company Arqule (ARQL), a developer of cancer therapies. They’re set to announce results of clinical trials next month -- and out with an earnings report Thursday.
The street loves this stock -- seven buy ratings and no sells. Howard Liang from Leerink Swann & Company is one of those analysts smitten with Arqule.
On April 4th he wrote that the company has "demonstrated drug discovery capability" and calls it "one of the most interesting early-stage companies developing targeted cancer therapy".
Arqule Chief Executive Dr. Steve Hill joins the guys for this conversation.
Dr. Hill explains that Arqule is developing medicines that kill cancer cells but leave normal cells alone.
What is the unique science you bring to the table, asks Dylan?
Cancer grows out of control and it doesn’t respond to signals that tell it to kill itself, explains Hill. Arqule is targeting both of those areas with a two pronged approach and one drug is showing positive results in early trials.
He adds ARQL is involved in two exciting partnerships. One is with a Japanese company which he thinks is the biggest deal ever between a bio-tech and Japanese company. The second is with Roche (RHHBY). In both cases, the companies assist with funding and share knowledge.
On May 2, 2007, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders;Strazzini Owns (C), (MPEL), (MER), (NWS-A) Bolling Owns (MPEL), Bolling Owns Natural Gas Futures
CNBC Is A Service Of NBC Universal And Dow Jones